ArticleJournal of neurology2019

Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.

Jessica Frau et al.PubMed ↗Publisher ↗

No numbers read from the abstract.